Moderna (MRNA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.97
- EPS estimate
- −$1.98
- EPS surprise
- +0.53%
- Revenue surprise
- +19.59%
- Revenue
- $145.0M
- Revenue estimate
- $121.2M
- Reported
- Jul 31, 2026
Moderna reported Q2 2026 results on July 31, 2026. It posted a loss of $1.97 per share, in line with the expected loss of $1.98, a 0.53% beat. Revenue was $145.0 million, ahead of the $121.2 million estimate by 19.59%. Compared with Q2 2025, the loss narrowed from $2.13 per share and revenue rose about 2% from $142.0 million.
Moderna earned $11.29 per share on $7.2 billion of revenue in Q4 2021, the highs in the table, and $19.96 per share across 2022. Annual results then turned to losses of $12.41 per share in 2023, $9.28 in 2024 and $7.27 in 2025. Eleven of the last 13 quarters were losses, including the low of $9.53 in Q3 2023. The first half of 2026 shows a loss of $5.37 per share, wider than $4.65 a year earlier, on revenue of $534 million, roughly double. Moderna beat the EPS estimate in 15 of the last 20 quarters.
Moderna reported Q3 between November 2 and November 7 in each of the last five years. That points to early November 2026 for the next report. In past years, Q3 and Q4 brought far more revenue than the first half.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 31, 2026 | −$1.98 | −$1.97 | +0.53% | $145.0M | SEC |
| Q1 2026 | May 1, 2026 | −$4.45 | −$3.40 | +23.53% | $389.0M | SEC |
| Q4 2025 | Feb 13, 2026 | −$2.54 | −$2.11 | +17.07% | $678.0M | SEC |
| Q3 2025 | Nov 6, 2025 | −$1.87 | −$0.51 | +72.79% | $1.0B | SEC |
| Q2 2025 | Aug 1, 2025 | −$2.99 | −$2.13 | +28.75% | $142.0M | SEC |
| Q1 2025 | May 1, 2025 | −$3.12 | −$2.52 | +19.13% | $108.0M | SEC |
| Q4 2024 | Feb 14, 2025 | −$2.68 | −$2.91 | −8.57% | $966.0M | SEC |
| Q3 2024 | Nov 7, 2024 | −$1.80 | $0.03 | +101.66% | $1.9B | SEC |
| Q2 2024 | Aug 1, 2024 | −$3.35 | −$3.33 | +0.54% | $241.0M | SEC |
| Q1 2024 | May 2, 2024 | −$3.56 | −$3.07 | +13.68% | $167.0M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.99 | $0.55 | +155.74% | $2.8B | SEC |
| Q3 2023 | Nov 2, 2023 | −$1.93 | −$9.53 | −393.19% | $1.8B | SEC |
| Q2 2023 | Aug 3, 2023 | −$3.93 | −$3.62 | +8.00% | $344.0M | SEC |
| Q1 2023 | May 4, 2023 | −$1.75 | $0.19 | +110.87% | $1.9B | SEC |
| Q4 2022 | Feb 23, 2023 | $4.60 | $3.61 | −21.54% | $5.1B | SEC |
| Q3 2022 | Nov 3, 2022 | $3.30 | $2.53 | −23.29% | $3.4B | SEC |
| Q2 2022 | Aug 3, 2022 | $4.58 | $5.24 | +14.33% | $4.7B | SEC |
| Q1 2022 | May 4, 2022 | $5.37 | $8.58 | +59.69% | $6.1B | SEC |
| Q4 2021 | Feb 24, 2022 | $9.96 | $11.29 | +13.33% | $7.2B | SEC |
| Q3 2021 | Nov 4, 2021 | $8.97 | $7.70 | −14.19% | $5.0B | SEC |
Quarterly revenue
Frequently asked questions
When did Moderna (MRNA) last report earnings?
Moderna last reported on Jul 31, 2026, covering fiscal Q2 2026.
Did MRNA beat earnings estimates?
Yes. Moderna reported EPS of −$1.97 for Q2 2026 against a −$1.98 estimate — a 0.53% beat.
How much revenue did MRNA report last quarter?
Moderna reported $145.0M in revenue for Q2 2026, against a consensus estimate of $121.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.